Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial

• Published in: Journal of translational medicine Vol. 21; no. 1; p. 411
• Main Authors: Yang, Guozhen, Su, Xiaodong, Huang, Yuanheng, Luo, Guangyu, Wang, Zhiqiang, Cai, Peiqiang, Zheng, Yating, Bei, Ting, Huang, Mengli, Bai, Yuezong, He, Haoqiang, Xiang, Jin, Cai, Muyan, Zhong, Jiudi, Guo, Qiyu, Zhang, Xu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 24.06.2023; BioMed Central; BMC
• Subjects: Capecitabine - therapeutic use; Care and treatment; Chemotherapy; Chemotherapy, Combination; Diagnosis; Dosage and administration; ESCC; Esophageal cancer; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - pathology; Esophageal Squamous Cell Carcinoma - drug therapy; Esophageal Squamous Cell Carcinoma - pathology; Humans; Immunotherapy; Neoadjuvant; Neoadjuvant Therapy; Neoplasm Recurrence, Local - drug therapy; Squamous cell carcinoma; Testing; China; Neoadjuvant; Chemotherapy; Immunotherapy; ESCC
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-023-04273-6

Two cycles of neoadjuvant PD-1 blockade plus chemotherapy induced favorable pathological response and tolerant toxicity in patients with locally advanced esophageal squamous cell carcinoma (ESCC). However, approximately 25% of patients relapsed within 1 year after surgery, indicating that a short course of treatment may not be sufficient. Therefore, exploring the effects of intensive treatment is needed for optimal clinical outcomes. Locally advanced ESCC patients were administered three cycles of camrelizumab plus nab-paclitaxel and capecitabine, followed by thoracoscopic esophagectomy. The primary endpoint was pathologic response. Secondary endpoints included safety, feasibility, radiologic response, survival outcomes, and immunologic/genomic correlates of efficacy. Forty-seven patients were enrolled in the study. Forty-two patients received surgery, and R0 resection was achieved in all cases. The complete and major pathological response rates were 33.3% and 64.3%, respectively, and the objective response rate was 80.0%. Three cycles of treatment significantly improved T down-staging compared to two cycles (P = 0.03). The most common treatment-related adverse events were grades 1-2, and no surgical delay was reported. With a median follow-up of 24.3 months, the 1-year disease-free survival and overall survival rates were both 97.6%, and the 2-year disease-free survival and overall survival rates were 92.3% and 97.6%, respectively. Three patients experienced disease recurrence or metastasis ranging from 12.5 to 25.8 months after surgery, and one patient died 6 months after surgery due to cardiovascular disease. Neither programmed death-ligand 1 expression nor tumor mutational burden was associated with pathological response. An increased infiltration of CD56 natural killer cells in the pretreatment tumor was correlated with better pathological response in the primary tumor. It seems probable that intensive cycles of neoadjuvant camrelizumab plus nab-paclitaxel and capecitabine increased tumor regression and improved survival outcomes. Randomized controlled trials with larger sample sizes and longer follow-up periods are needed to validate these findings. Trial registration Chinese Clinical Trial Registry, ChiCTR2000029807, Registered February 14, 2020, https://www.chictr.org.cn/showproj.aspx?proj=49459 .